292 related articles for article (PubMed ID: 25381083)
21. [Progress in research of pragmatic-explanatory continuum indicator summary].
Hu G; Hu Y; Zhan S
Zhonghua Liu Xing Bing Xue Za Zhi; 2016 Mar; 37(3):439-42. PubMed ID: 27005554
[TBL] [Abstract][Full Text] [Related]
22. The role of pragmatism in explaining heterogeneity in meta-analyses of randomised trials: a protocol for a cross-sectional methodological review.
Aves T; Allan KS; Lawson D; Nieuwlaat R; Beyene J; Mbuagbaw L
BMJ Open; 2017 Sep; 7(9):e017887. PubMed ID: 28871028
[TBL] [Abstract][Full Text] [Related]
23. How pragmatic or explanatory is the randomized, controlled trial? The application and enhancement of the PRECIS tool to the evaluation of a smoking cessation trial.
Selby P; Brosky G; Oh PI; Raymond V; Ranger S
BMC Med Res Methodol; 2012 Jul; 12():101. PubMed ID: 22824225
[TBL] [Abstract][Full Text] [Related]
24. Analysis of the characteristics and the degree of pragmatism exhibited by pragmatic-labelled trials of antineoplastic treatments.
Saesen R; Depreytere K; Krupianskaya K; Langeweg J; Verheecke J; Lacombe D; Huys I
BMC Med Res Methodol; 2023 Jun; 23(1):148. PubMed ID: 37355603
[TBL] [Abstract][Full Text] [Related]
25. CHARTing a Path to Pragmatic Tobacco Treatment Research.
Cruvinel E; Richter KP; Stoney C; Duffy S; Fellows J; Harrington KF; Rigotti NA; Sherman S; Tindle HA; Shireman TI; Shelley D; Waiwaiole L; Cummins S
Am J Prev Med; 2016 Oct; 51(4):630-6. PubMed ID: 27647063
[TBL] [Abstract][Full Text] [Related]
26. Trends in the Explanatory or Pragmatic Nature of Cardiovascular Clinical Trials Over 2 Decades.
Sepehrvand N; Alemayehu W; Das D; Gupta AK; Gouda P; Ghimire A; Du AX; Hatami S; Babadagli HE; Verma S; Kashour Z; Ezekowitz JA
JAMA Cardiol; 2019 Nov; 4(11):1122-1128. PubMed ID: 31473763
[TBL] [Abstract][Full Text] [Related]
27. How pragmatic are randomized trials of remdesivir and favipiravir for in-hospital treatment of COVID-19: a descriptive methodological review of trial design using the PRECIS-2 framework.
Sharma T; Qamar I; Zwarenstein M
J Clin Epidemiol; 2022 Dec; 152():193-200. PubMed ID: 36265553
[TBL] [Abstract][Full Text] [Related]
28. The PRECIS-2 tool seems not to be useful to discriminate the degree of pragmatism of medicine masked trials from that of open-label trials.
Dal-Ré R
Eur J Clin Pharmacol; 2021 Apr; 77(4):539-546. PubMed ID: 33106910
[TBL] [Abstract][Full Text] [Related]
29. Making clinical trials more relevant: improving and validating the PRECIS tool for matching trial design decisions to trial purpose.
Loudon K; Zwarenstein M; Sullivan F; Donnan P; Treweek S
Trials; 2013 Apr; 14():115. PubMed ID: 23782862
[TBL] [Abstract][Full Text] [Related]
30. An application of PRECIS-2 to evaluate trial design in a pilot cluster randomised controlled trial of a community-based smoking cessation intervention for women living in disadvantaged areas of Ireland.
Darker C; Loudon K; O'Connell N; Castello S; Burke E; Vance J; Reynolds C; Buggy A; Dougall N; Williams P; Dobbie F; Bauld L; Hayes CB
Pilot Feasibility Stud; 2022 Jan; 8(1):19. PubMed ID: 35078530
[TBL] [Abstract][Full Text] [Related]
31. PRECIS-2 analysis of pragmatic acupuncture trials: a systematic review.
Lim J; Lee H; Kim YS
BMC Complement Med Ther; 2024 May; 24(1):181. PubMed ID: 38702632
[TBL] [Abstract][Full Text] [Related]
32. Designing Trials with Purpose: Pragmatic Clinical Trials of Nonpharmacological Approaches for Pain Management.
Gordon KS; Peduzzi P; Kerns RD
Pain Med; 2020 Dec; 21(Suppl 2):S7-S12. PubMed ID: 33313727
[TBL] [Abstract][Full Text] [Related]
33. Pragmatic Trials in Genomic Medicine: The Integrating Pharmacogenetics In Clinical Care (I-PICC) Study.
Brunette CA; Miller SJ; Majahalme N; Hau C; MacMullen L; Advani S; Ludin SA; Zimolzak AJ; Vassy JL
Clin Transl Sci; 2020 Mar; 13(2):381-390. PubMed ID: 31808996
[TBL] [Abstract][Full Text] [Related]
34. Generalizability of randomized controlled trials in primary health care: Applying the PRECIS-2 tool on published protocols.
Papagiannopoulou E; Laiou E; Tatsi C; Dimakopoulos G; Ntzani EE; Siamopoulos K; Tatsioni A
J Eval Clin Pract; 2023 Mar; 29(2):253-262. PubMed ID: 36072984
[TBL] [Abstract][Full Text] [Related]
35. Facing the Realities of Pragmatic Design Choices in Environmental Health Studies: Experiences from the Household Air Pollution Intervention Network Trial.
Checkley W; Hossen S; Rosa G; Thompson LM; McCracken JP; Diaz-Artiga A; Balakrishnan K; Simkovich SM; Underhill LJ; Nicolaou L; Hartinger SM; Davila-Roman VG; Kirby MA; Clasen TF; Rosenthal J; Peel JL; On Behalf Of Household Air Pollution Intervention Network Hapin Investigators
Int J Environ Res Public Health; 2022 Mar; 19(7):. PubMed ID: 35409475
[TBL] [Abstract][Full Text] [Related]
36. Designing pragmatic trials-what can we learn from lessons learned?
Groenwold RHH; Dekkers OM
J Clin Epidemiol; 2017 Oct; 90():3-5. PubMed ID: 28629700
[TBL] [Abstract][Full Text] [Related]
37. Intervention Fidelity in Pain Pragmatic Trials for Nonpharmacologic Pain Management: Nuanced Considerations for Determining PRECIS-2 Flexibility in Delivery and Adherence.
Kerns RD; Davis AF; Fritz JM; Keefe FJ; Peduzzi P; Rhon DI; Taylor SL; Vining R; Yu Q; Zeliadt SB; George SZ
J Pain; 2023 Apr; 24(4):568-574. PubMed ID: 36574858
[TBL] [Abstract][Full Text] [Related]
38. Applying the Pragmatic-Explanatory Continuum Indicator Summary Model in a Primary Care-Based Lifestyle Intervention Trial.
Rosas LG; Lv N; Azar K; Xiao L; Yank V; Ma J
Am J Prev Med; 2015 Sep; 49(3 Suppl 2):S208-14. PubMed ID: 26296556
[TBL] [Abstract][Full Text] [Related]
39. The PRECIS-2 tool has good interrater reliability and modest discriminant validity.
Loudon K; Zwarenstein M; Sullivan FM; Donnan PT; Gágyor I; Hobbelen HJSM; Althabe F; Krishnan JA; Treweek S
J Clin Epidemiol; 2017 Aug; 88():113-121. PubMed ID: 28603007
[TBL] [Abstract][Full Text] [Related]
40. Informing real-world practice with real-world evidence: the value of PRECIS-2.
Neta G; Johnson KE
BMC Med; 2018 May; 16(1):76. PubMed ID: 29783964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
